Volume : 11, Issue : 12, December – 2024
Title:
MODALITIES OF TREATMENT OF CROHN’S DISEASE
Authors :
Shurouq Hamza Arkoubi*, Badeah Mohammed A Shabee, Wejdan Mousa Zakan3, Manal Yahya Sofyani, Fatimah Ali A Haddadi, Hind Saeed Alotaibi, Raghad Yahya Mathkor, Heba Omar Abdulrahman Melebary, Shatha Tatiq Mohammd Qadi, Rodha Anwar Altalyouni, Tahani Omar Malibari, Abdulaziz Mohammed Aljaber, Abdallah Hammad Salamh Alhity, Batool Abbas Almishkab
Abstract :
Background: A chronic bowel disorder, Crohn’s disease (CD) is indicated by a dysfunctional immune response driven by genetic and environmental variables. The disorder significantly influences adults who are 20 to 40 years old, especially in those of Jewish lineage, whereas fewer cases are observed in African-descendant communities. Signs of the condition may involve experiencing stomach discomfort, persistent loose stools, unintentional weight reduction, and other symptoms impacting the skin, joints, and various organs. Genetic factors, notably mutations in the NOD2 gene, and dysregulated TH1 immune responses play pivotal roles in sustaining mucosal inflammation. Diagnosis necessitates thorough evaluations, comprising clinical assessments, endoscopy, advanced imaging modalities like MRI, and laboratory analyses. Instruments such as the CDEIS and SES-CD indices assess disease severity and track treatment efficacy. Management methods concentrate on symptom relief, the upkeep of remission, and bespoke treatments that utilize corticosteroids, immunosuppressants, or biologics such as infliximab. Complications encompass intestinal obstructions, fistulas, and vascular inflammation. Epidemiological investigations indicate rising incidence rates, especially in urban settings, alongside significant diagnostic delays for some patients, emphasizing the imperative for enhanced awareness and early identification. Managing Crohn’s disease involves a comprehensive strategy combining diagnostic and treatment methods for effective results.
Objective: an overview of the Epidemiology, Prevalence, Risk Factors, and Progression of (CD).
Methods: a comprehensive review of Modalities of treatment of Crohn’s disease. The PUBMED and Google Scholar search engines were the main databases used for the search process, with articles collected from 1990 to 2024.
Conclusion: Crohn’s disease (CD) represents a complex inflammatory bowel condition that requires a thorough management strategy incorporating medical, psychological, nutritional, and educational elements. Treatment aims to achieve remission, avert complications, and enhance patient quality of life. Medical interventions, such as corticosteroids and biologics, focus on inflammation reduction and relapse prevention, while surgery is utilized for complications like obstructions. The realm of Complementary and Alternative Medicine (CAM) presents holistic solutions, featuring herbal solutions and mind-body practices that bolster standard medical treatment. Dietary strategies, particularly enteral nutrition, are pivotal, alongside educational initiatives that empower patients in health management. Psychological support addresses the mental health issues associated with CD, employing psychoeducation and therapies like Acceptance and Commitment Therapy (ACT) to promote resilience. Support groups foster community and coping mechanisms. Holistic care combines these methodologies, prioritizing education, self-management, and individualized support to tackle the diverse impacts of CD. Steady investigation and innovation are key for enhancing therapeutic practices, uplifting patient results, and raising the life quality for those dealing with Crohn’s disease.
Keywords: Crohn’s Disease (CD), Surgical Interventions, Risk Factors, Laboratory, Management.
Cite This Article:
Please cite this article in press Shurouq Hamza Arkoubi et al., Modalities Of Treatment Of Crohn’s Disease .,Indo Am. J. P. Sci, 2024; 11 (12).
Number of Downloads : 10
References:
1. Pierelli L, Rutella S, Bonanno G. Cell and Stem-Cell Therapies of Crohn’s Disease and Complications. In: Tersigni R, Prantera C, editors. Crohn’s Disease: A Multidisciplinary Approach. Milano: Springer Milan; 2010. p. 131-41.
2. Weinstock JV. Crohn’s Disease. Granulomatous Infections and Inflammations2003. p. 293-320.
3. Wei Z, Baldassano S, Hakonarson H. Genetics of Inflammatory Bowel Diseases. In: Mamula P, Markowitz JE, Baldassano RN, editors. Pediatric Inflammatory Bowel Disease. New York, NY: Springer New York; 2013. p. 3-12.
4. Intestinal Crohn’s disease: management. Revista da Associação Médica Brasileira (English Edition). 2011;57(1):10-3.
5. Pounder REJJoG. The pathogenesis of Crohn’s disease. 1994;29:11-5.
6. Collins SM, Croitoru K. Pathophysiology of inflammatory bowel disease: the effect of inflammation on intestinal function. In: Targan SR, Shanahan F, Karp LC, editors. Inflammatory Bowel Disease: From Bench to Bedside. Boston, MA: Springer US; 2005. p. 223-34.
7. Benevento G, Avellini C, Terrosu G, Geraci M, Lodolo I, Sorrentino D. Diagnosis and assessment of Crohn’s disease: the present and the future. Expert Review of Gastroenterology & Hepatology. 2010;4(6):757-66.
8. Vos FM, Tielbeek JAW, Naziroglu RE, Li Z, Schueffler P, Mahapatra D, et al., editors. Computational modeling for assessment of IBD: To be or not to be? 2012 Annual International Conference of the IEEE Engineering in Medicine and Biology Society; 2012 28 Aug.-1 Sept. 2012.
9. Novak G, Parker CE, Pai RK, MacDonald JK, Feagan BG, Sandborn WJ, et al. Histologic scoring indices for evaluation of disease activity in Crohn’s disease. Cochrane Database of Systematic Reviews. 2017(7).
10. Li Z. Image registration for assessment of Crohn’s disease severity. 2015.
11. Gee MS, Harisinghani MG. MRI in patients with inflammatory bowel disease. Journal of magnetic resonance imaging : JMRI. 2011;33(3):527-34.
12. Mocanu D, Catuneanu A-M, Diculescu M, Gologan S, Sporea IJM. Current epidemiologic trends in Crohn’s disease: data from a tertiary referral centre in Bucharest:(Fundeni Institute, Center of Gastroenterology and Hepatology). 2010;5(2):95.
13. Hovde Ø, Moum BAJWjogW. Epidemiology and clinical course of Crohn’s disease: results from observational studies. 2012;18(15):1723.
14. Lind E, Fausa O, Elgjo K, Gjone E. Clinical Manifestations. Scandinavian Journal of Gastroenterology. 1985;20(6):665-70.
15. Radwan-Kwiatek K, Wójtowicz-Chomicz K, Radwan P, Skrzydło-Radomska B, Borzecki AJPL. Impact of cigarette smoking on the clinical outcome of Crohn’s disease. 2009;66(10):567-70.
16. Colombel J, Gower-Rousseau CJPM. Etiology of Crohn disease. Current data. 1994;23(12):558-60.
17. Ananthakrishnan ANJG, hepatology. Environmental risk factors for inflammatory bowel disease. 2013;9(6):367.
18. IRVING PM, GEARRY RB, SPARROW MP, GIBSON PR. Review article: appropriate use of corticosteroids in Crohn’s disease. 2007;26(3):313-29.
19. Steinhart H. Maintenance Therapy in Crohn′s Disease. 2000;14(C):480782.
20. Hibi T, Hisamatsu T. Choice of Immunosuppressive Therapy. In: Chen CW, Cheng J, Ginès P, Ouyang Q, Schölmerich J, editors. Gut and Liver: Falk Symposium 174, Beijing, August 2010: S.Karger AG; 2011. p. 0.
21. McCartney S, Farthing MJG. Advances in the Medical Treatment of Crohn’s Disease. In: Beynon J, Carr ND, editors. Progress in Colorectal Surgery. London: Springer London; 2005. p. 59-92.
22. Kakkar A, Wasan SK, Farraye FAJG, hepatology. Targeting mucosal healing in Crohn’s disease. 2011;7(6):374.
23. Perdomo JA, Iwagaki H, Hizuta A, Mizuno M, Nakagawa H, Tanaka N, et al. Surgical treatment for Crohn’s disease. 1995;49(2):113-5.
24. Jeong SY, Moon JS, Park KJ, Kim YS. Successful treatment of postoperative fistula with infliximab in a patient with Crohn’s disease. Intestinal research. 2014;12(1):74-7.
25. Park EJ, Baik SH. Surgery in Inflammatory Bowel Diseases. In: Kim WH, Cheon JH, editors. Atlas of Inflammatory Bowel Diseases. Berlin, Heidelberg: Springer Berlin Heidelberg; 2015. p. 201-28.
26. KRZNARIĆ Ž, KOLAČEK S, VRANEŠIĆ BENDER D, LJUBAS KELEČIĆ D, ČUKOVIĆ-ČAVKA S, MIJANDRUŠIĆ SINČIĆ B, et al. Croatian guidelines for use of enteral nutrition in Crohn’s disease. 2010;132(1-2):1-7.
27. Fukuda Y, Kosaka T, Okui M, Hirakawa H, Shimoyama TJJog. Efficacy of nutritional therapy for active Crohn’s disease. 1995;30:83-7.
28. Afonso J, Rombeau JJH-g. Nutritional care for patients with Crohn’s disease. 1990;37(1):32-41.
29. Jarema MJNel. Herbal drug treatment. 2008;29:93-104.
30. Sointu E. Complementary and Alternative Medicine. The Wiley Blackwell Encyclopedia of Health, Illness, Behavior, and Society. p. 283-90.
31. Tripathy JP. Can naturopathy provide answers to the escalating health care costs in India? Journal of Traditional and Complementary Medicine. 2015;5(2):63-5.
32. Pfeffer-Gik T, Levine A. Dietary Clues to the Pathogenesis of Crohn’s Disease. Digestive Diseases. 2014;32(4):389-94.
33. Rolfe VE, Fortun PJ, Hawkey CJ, Bath‐Hextall FJ. Probiotics for maintenance of remission in Crohn’s disease. Cochrane Database of Systematic Reviews. 2006(4).
34. Post-White J, Ndao DH. Mind-Body Medicine. In: Längler A, Mansky PJ, Seifert G, editors. Integrative Pediatric Oncology. Berlin, Heidelberg: Springer Berlin Heidelberg; 2012. p. 79-108.
35. 橋本英樹, 岩男泰, 日比紀文, 上野文昭, 宮原透, 杉田昭, et al. 慢性期クローン病患者 QOL のモデル化の試み―臨床・心理・社会的特性の複合的影響について―. 1999;96(11):1258-65.
36. Maunder RG. Psychotherapy for inflammatory bowel disease: new prospects. In: Williams CN, Bursey RF, Gall DG, Martin F, McLeod RS, Sutherland LR, et al., editors. Trends in Inflammatory Bowel Disease Therapy 1999: The proceedings of a symposium organized by AXCAN PHARMA, held in Vancouver, BC, August 27–29, 1999. Dordrecht: Springer Netherlands; 2000. p. 185-93.
37. Maunder RG, Esplen MJ. Supportive-Expressive Group Psychotherapy for Persons with Inflammatory Bowel Disease. 2001;46(7):622-6.
38. Rakovec-Felser ZJCa. The biopsychosocial model of treatment the patients with inflammatory chronic bowel disease. 2011;35(2):453-61.
39. Faller H, Ehlebracht-König I, Reusch A. Empowerment durch Patientenschulung in der Rheumatologie. Zeitschrift für Rheumatologie. 2015;74(7):603-8.
40. Lee J, Allen R, Ashley S, Becker S, Cummins P, Gbadamosi A, et al. British Dietetic Association evidence-based guidelines for the dietary management of Crohn’s disease in adults. 2014;27(3):207-18.
41. Kim SB, Kim KO, Jang BI, Kim ES, Cho KB, Park KS, et al. Patients’ beliefs and attitudes about their treatment for inflammatory bowel disease in Korea. 2016;31(3):575-80.
42. Rodis JL, Kibbe P. Development of a hepatitis C support group. American Journal of Health-System Pharmacy. 2006;63(17):1594-6.